Aug 7 |
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update
|
Jun 19 |
Are Medical Stocks Lagging DURECT (DRRX) This Year?
|
May 21 |
DURECT gets FDA breakthrough therapy status for larsucosterol
|
May 21 |
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
|
May 14 |
Q1 2024 DURECT Corp Earnings Call
|
May 14 |
Durect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...
|
May 14 |
DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript
|
May 13 |
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
|
May 13 |
DURECT GAAP EPS of -$0.25 misses by $0.03, revenue of $1.83M misses by $0.9M
|
May 13 |
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
|